Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BNY).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures: FTSE +0.10%, DAX +0.42%, CAC40 +0.20%

Oct 21 ,2026

  • Synopsis

    • European equity markets are set for a positive open amidst mixed Asia equities on Wednesday. Hong Kong and mainland China faded from a positive start, joining Australia as the laggards. South Korea extended a rally on the open -- Elice (015850-KR) up 30% after yesterday's debut slump -- Japan and Taiwan maintaining solid gains though off best levels. Regional sector skew aligning with respective benchmarks. Tech majors broadly higher in stronger markets, mixed elsewhere. US futures higher on the back of after-hours earnings, extending cash session strength.

    • Attention also on the crude oil reversal. Overnight declines were attributed to reports US and Iran are close to an agreement (subsequently reported as inaccurate) and mediation efforts to quell Houthi attacks though rebound in Asia came after another report indicating Iran dragging out US talks to weaken Trump's position ahead of the US midterm elections

    • Back in Europe, after UK MPs questions on Northern Ireland there's weekly PMQs at 12noon BST, followed shortly thereafter by Opposition day debate (Liberal Democrats, subject tba). Committee topics include scrutiny of the draft Heathrow expansion National Policy Statement at 9:15, Scotland's whisky industry: Tariffs, trade and growth at 9:30, energy resilience at 10:00, the same time as dunkelflaute and the risks of electricity intermittency. EU's Zaharieva at the Bill Gates Foundation Roundtable: AI, equity and Europe's choice. In Germany, Chancellor Merz speech, moderated discussion at Berlin Global Dialogue. Frankfurt Finance & Future Summit takes place and there is PUSU deadline in connection with Circle8 (CIRC) possible offer for Sthree (STEM.LN).

    • In central banks, ECB's Lane panellist at 6:15CET at CF40-Euro50 Closed-Door Luncheon and Bundesbank's Nagel speech at 8:15CET at event hosted by International Bankers Forum. ECB's Cipollone presentation at 10:00CET at Associazione Bancaria Italiana's Executive Committee Meeting. BOE's Bailey discussion at 14:00BST at event organised by OMFIF and ECB's Lagarde in on-stage conversation at Museum Reinhard Ernst in Wiesbaden, Germany. Bundesbank's Mauderer panellist at 15:15CET at Berlin Global Dialogue 2026 (agenda, Tue-Thu, livestream, also company execs and politicians speaking) whilst Bundesbank publishes its latest monthly report at 12noon CET. Bundesbank's Lienenkämper gives a speech at 17:00CET at the change-in-leadership ceremony at one of bank's regional offices.

    • Macro data due include UK Sep CPI/RPI/PPI input/output and PSNB

    • Earnings include from the Beleux region, Randstad (RAND.NA) and Akzo Nobel (AKZA.NA) whilst in the DACHs region, Adidas (ADS.GR), Deutsche Börse (DB1.GR) and Telekom Austria (TKA.AV) updated investors. In the Nordics, DSV (DSV.DC), DNB Bank (DNB.NO), SKF (SKF.B.SS), Svenska Handelsbanken (SHB.A.SS), Husqvarna (HUSQ.B.SS), Vår Energi (VAR.NO) and Storebrand (STB.NO) released results, with DSV narrowing its FY26 outlook and reporting that the Schenker integration is progressing as planned. In France, EssilorLuxottica (EL.FP), Michelin (ML.FP), Carrefour (CA.FP), Edenred (EDEN.FP), Eurofins Scientific (ERF.FP), Bureau Veritas (BVI.FP) and Atos (ATO.FP) reported results, with Eurofins warning FY26 organic growth is likely to fall below its previous objective.

    • Also reporting today are SAP (SAP.GR), Renk Group (R3NK.GR) and flatexDEGIRO (FTK.GR), Getinge (GETI.B.SS), Moncler (MONC.IM), Iberdrola (IBE.SM), Fresnillo (FRES.LN), Aberdeen Group (ABDN.LN) and Quilter (QLT.LN).

  • Top company news

    • Earnings/updates

      • Benelux

        • RAND.NA (Randstad) -- reports Q3 EPS €0.75 ex-items vs consensus €0.71

        • AKZA.NA (Akzo Nobel) -- reports Q3 adjusted operating income €297M vs consensus €296M

        • BFIT.NA (Basic-Fit) -- reports 9M revenue €1.22B vs year-ago €1.03B; reiterates FY26 outlook

      • DACHs

        • ADS.GR (Adidas) -- reports preliminary Q3 revenue €7.25B vs FactSet €7.11B [15 est, €6.77-7.25B]

        • DB1.GR (Deutsche Börse) -- reports Q3 EPS €3.10 vs consensus €3.05

        • TKA.AV (Telekom Austria) -- reports Q3 net income €195M vs consensus €195M; increases guidance for 2026 total revenue growth

        • FORN.SW (Forbo Holding) -- presents transformation roadmap and 2029 financial targets - CMD

        • VH2.GR (Friedrich Vorwerk Group) -- reports Q3 revenue €228.3M, +13% vs year-ago €202M; raises FY outlook

      • Nordics

        • SHB.A.SS (Svenska Handelsbanken) -- reports Q3 EPS SEK2.87 vs FactSet SEK2.90 [13 est, SEK2.82-2.97]

        • HUSQ.B.SS (Husqvarna) -- reports Q3 EPS (ex IAC) (SEK0.58) vs FactSet (SEK0.32) [7 est, (SEK0.43)-(0.20)]

        • ORNBV.FH (Orion) -- guides FY26 revenue €2.07B-2.14B vs prior guidance €2.00B-2.10B and FactSet €2.11B [7 est, €2.09-2.14B]

        • VAR.NO (Vår Energi) -- reports Q3 cash from operations $1.52B vs FactSet $1.89B

        • STB.NO (Storebrand) -- reports Q3 cash equivalent earnings after tax NOK996M vs consensus NOK1.07B; intends share buybacks of NOK2B for 2027 vs prior announcement NOK1.5B

        • WIHL.SS (Wihlborgs Fastigheter) -- reports Q3 EPRA NRV per share SEK101.59 vs year-ago SEK99.66

        • SKF.B.SS (SKF) -- reports Q3 adj. operating profit SEK2.85B vs consensus SEK2.77B; guides Q4

        • ELISA.FH (Elisa Oyj) -- reports Q3 comparable EPS €0.59 vs consensus €0.64

        • MIPS.SS (MIPS) -- reports Q3 EPS SEK1.48 vs FactSet SEK2.08 [6 est, SEK1.30-2.86]

        • RILBA.DC (Ringkjøbing Landbobank) -- reports Q3 EPS DKK26.2 vs FactSet DKK26.08 [4 est, DKK25.75-26.40]; expects FY net profit in upper part of guidance range

        • SECARE.SS (Swedencare) -- reports Q3 EPS SEK0.18 vs FactSet SEK0.33 [4 est, SEK0.28-0.38]; confirms financial targets

        • FABG.SS (Fabege) -- reports Q3 EPRA NRV per share 147 vs FactSet 144.80

        • DNB.NO (DNB Bank) -- reports Q3 net income NOK9.37B vs consensus NOK8.65B

        • HMS.SS (HMS Networks) -- reports Q3 EPS SEK3.82 ex-items vs FactSet SEK3.83 [6 est, SEK3.55-4.10]

        • DYVOX.SS (Dynavox Group) -- reports Q3 EPS SEK0.83 vs FactSet SEK0.76 [4 est, SEK0.70-0.80]; confirms financial targets

        • DSV.DC (DSV A/S) -- reports Q3 net income DKK3.02B vs consensus DKK2.67B; narrows FY26 outlook; Schenker integration generally progressing as planned

        • ARCH.NO (Archer) -- Q3 trading update; revenue $268M vs FactSet $274.8M [2 est, $262.5-287M]

        • BERG.B.SS (Bergman & Beving) -- reports Q2 adjusted net income SEK67M vs FactSet SEK60.4M

        • INWI.SS (Inwido) -- reports Q3 EPS SEK3.48 vs FactSet SEK3.54 [5 est, SEK3.24-3.88]

      • France

        • EL.FP (EssilorLuxottica) -- reports Q3 revenue €7.49B vs consensus €7.35B

        • ML.FP (Cie Generale des Etablissements Michelin SA) -- reports Q3 revenue €6.49B vs consensus €6.55B

        • CA.FP (Carrefour) -- reports Q3 sales inc. VAT (pre-IAS 29) €22.69B vs consensus €22.71B

        • EDEN.FP (Edenred) -- reports Q3 total revenue €725M vs consensus €710.5M; confirms FY26 guidance

        • ERF.FP (Eurofins Scientific) -- reports Q3 revenue €1.91B vs StreetAccount €1.89B; organic growth +3.5% vs SA +3.2%; FY26 organic growth likely to be below previous mid-single-digit objective

        • LI.FP (Klepierre) -- raises FY26 EBITDA guidance to €1.17B vs prior €1.15B

        • SFER.IM (Salvatore Ferragamo) -- reports 9M total revenues €675M vs consensus €675.4M

        • VIV.FP (Vivendi) -- reports Q3 revenue €77M vs year-ago €68M

        • VU.FP (VusionGroup) -- reports Q3 IFRS sales €432.6M, +24% vs year-ago €347.8M

        • ICAD.FP (Icade) -- reports 9M revenue €887.1M, (4%) vs year-ago €923M; FY26 guidance unchanged

        • OPM.FP (OPmobility) -- reports Q3 revenue €2.44B, +3% vs year-ago €2.36B

        • ITP.FP (Interparfums) -- reports Q3 revenue €265.5M vs year-ago €253.5M; targets top of FY26 sales guidance of ~€870M

        • BVI.FP (Bureau Veritas) -- reports Q3 revenue €1.57B vs consensus €1.55B

        • ATO.FP (ATOS SE) -- reports Q3 revenue €1.64B vs FactSet €1.61B [1 est]

      • UK

        • SRB.LN (Serabi Gold) -- reports Q3 gold production 11,008 oz, (9%) y/y

    • M&A

      • EN.FP (Colas) -- completes the acquisition of Suit-Kote Corporation, a leading road solutions specialist in the United States

      • SIP.BB (Sipef) -- holder Ackermans & van Haaren raises stake above 45% as at 30-Sep

      • QGEN (Qiagen) -- EQT AB (EQT.SS) reported to be in advanced talks to purchase Qiagen -- Bloomberg, citing sources

      • TIT.IM (Telecom Italia) -- MEF and Retelit confirm commitment to complete Sparkle acquisition, update by 20-Nov

      • 4004.JP (Resonac Holdings) -- Sika Group to acquire adhesives business of Resonac Corporation; terms undisclosed

      • FNAC.FP (Fnac Darty) -- merger with EP Group to close on 9-Nov

      • GYC.GR (Grand City Properties) -- acquires 20% stake in LEG Immobilien SE

      • ALFLE.FP (Fleury Michon) -- acquires All Plants

      • Castore in talks to sell itself - FT

    • Healthcare

      • GSK.LN (GSK Plc) -- FDA approves Hibsago to treat hepatitis B in certain adults

      • BAYN.GR (Bayer AG) -- FDA approves Zydus Pharma generic of Bayer's Climara Pro

      • FME.GR (Fresenius Medical Care) -- FDA approves Fresenius Medical's Calrezdy and Cienby for use during hemodialysis or hemodiafiltration

      • GALD.SW (Galderma Group) -- Galderma to showcase data from its innovative Injectable Aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC)

      • HNSA.SS (Hansa Biopharma) -- announces Idefirix PAES late-breaking abstract presentation at ASN Kidney Week

      • VICO.SS (Vicore Pharma Holding) -- Transcript Intelligence: Vicore Pharma Holding at Chardan Healthcare Conference

      • XVIVO.SS (Xvivo Perfusion) -- NICE makes early-use recommendation for XPS to assess and recondition marginal lungs for transplantation

      • FYB.GR (Formycon) -- Formycon, Biocelys to collaborate on new biosimilar project FYB286; terms undisclosed

      • IBAB.BB (Ion Beam Applications) -- announces first patient treated in the C-FLASH-01 ConformalFLASH clinical trial

      • OSE.FP (OSE Immunotherapeutics) -- Transcript Intelligence: OSE Immunotherapeutics at Chardan Healthcare Conference

    • Other

      • DSV.DC (DSV ) -- announces launch of share buyback for maximum of DKK 1.50B

      • FHZN.SW (Flughafen Zuerich) -- COO Stefan Tschudin to leave by mutual, amicable agreement in mid-2027

      • SKA.B.SS (Skanska) -- signs contract with New York City Department of Design and Construction to construct new waterfront connection in New York City, US; contract is worth $163M, about SEK 1.5B

      • ZEHN.SW (Zehnder Group) -- and BBMG Corporation announces liquidation of JV Zehnder (China) Indoor Climate Co., Ltd. in Beijing

      • ENDUR.NO (Endur) -- wholly owned subsidiary Total Betong sees backlog increase connected with projects for K2 Stavanger

      • SPIE.FP (SPIE) -- completes refinancing of its ORNANEs due January 2028

      • THULE.SS (Thule Group) -- Chairman Hans Eckerström resigns with immediate effect following EGM request from certain shareholders

      • THEON.NA (Theon International) -- awarded night vision contracts worth €45M

  • Key rating changes

    • Upgrades

      • STAN.LN (Standard Chartered) -- to overweight from equal weight at Barclays

      • LR.FP (Legrand) -- to buy from neutral at Goldman Sachs

      • IG.IM (Italgas) -- buy from hold at Kepler Cheuvreux

      • ABB.SS (ABB Limited) -- to buy from hold at ABG Sundal Collier

      • DKSH.SW (DKSH Holding) -- to outperform from neutral at BNP Paribas Exane

      • FBK.IM (FinecoBank) -- to outperform from market perform at Keefe, Bruyette & Woods

    • Downgrades

      • MUM.GR (Mensch & Maschine Software) -- hold from buy at Deutsche Bank

      • CA.FP (Carrefour) --

        • to hold from buy at Kepler Cheuvreux

        • to equal-weight from overweight at Morgan Stanley

      • CKN.LN (Clarkson) -- Clarkson resumed add at Peel Hunt; prior rating was buy

    • Initiations

      • Barclays initiates PPET.LN; upgrades MNTN.LN; downgrades ICGT.LN, PIN.LN

      • GBLB.BB (Groupe Bruxelles Lambert) -- buy at Berenberg

  • Data

    • Nikkei +0.99% to 64707.30

    • Hang Seng (0.49%) to 23751.60

    • Shanghai Composite (0.49%) to 3717.02

    • S&P futures +18.3 vs prior close of 7755.3

    • €-$ (0.0017) or (0.15%) to 1.1222

    • $-¥ +0.02 or +0.01% to 158.19

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

    • BNY.com Terms of Use Privacy Cookie Notice Manage Cookies Disclaimer CUSIP Disclaimer

    • ©  2025 The Bank of New York Corporation. Depositary Receipt business and services are conducted through The Bank of New York.